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Summary
Gigaxonin is mutated in human giant axonal neuropa-
thy (GAN), an autosomal recessive neurodegenerative
disorder. The presence of generalized cytoskeletal
abnormalities [1, 2], including few microtubules and
accumulated intermediate filaments (IFs), in GAN sug-
gests an essential role of gigaxonin in cytoskeletal or-
ganization and dynamics. However, the molecular
mechanisms underlying the cytoskeletal pathology re-
main to be elucidated. Over the years, the ubiquitin-
proteasome system (UPS) of intracellular protein deg-
radation has been implicated in the control of many
fundamental cellular processes. Defects in this system
seem tobedirectly linked to thedevelopment ofhuman
diseases, including cancers and neurodegenerative
diseases [3, 4]. Here, we show that gigaxonin controls
protein degradation of tubulin folding cofactor B
(TBCB) [5], a function disrupted by GAN-associated
mutations. The substantial TBCB protein accumula-
tion caused by impaired UPSmay be a causative factor
of cytoskeletal pathology in GAN. Our study provides
important insight into pathogenesis of neurodegener-
ative diseases associated with cytoskeletal abnormal-
ities.
Results and Discussion
Gigaxonin Binds to Tubulin Folding Factor B
Gigaxonin lacks direct binding sites for the cytoskeletal
network [6]. We have previously identified the light chain
of microtubule-associated protein (MAB-1B-LC) as a
neuronal specific binding partner of gigaxonin [6]. How-
ever, because of its restricted expression pattern, dis-
ruption of the gigaxonin-MAP1B-LC interaction could
not account for the generalized cytoskeletal abnormal-
ity. The multiple tissue involvement of GAN pathology
led us to predict that a widely expressed partner of giga-
xonin may exist. In the initial yeast two-hybrid screen,
*Correspondence: yanmin.yang@stanford.edutubulin folding co-factor B (TBCB, amino acids 32–244)
was identified as another interacting factor of gigaxonin
(Figure 1A). Unlike MAP1B, TBCB is a ubiquitously
expressed tubulin chaperone protein and binds to
a-tubulin, a microtubule building unit [5, 7, 8]. The spe-
cific interaction was confirmed with pulldown assays,
revealing that the kelch-repeat domain of gigaxonin
contains the site responsible for the interaction with the
N-terminal segment of TBCB (Figure 1B, lanes 3 and 5).
Furthermore, in COS7 cells that express no detectable
gigaxonin [6], the wild-type gigaxonin (Flag-Gig), but
not the truncated mutant form (Flag-GigR293X), could
coimmunoprecipitate endogenous protein of TBCB
(Figure 1C) detected by TBCB specific antibody (Figure
S1 in the Supplemental Data available with this article
online). To further assess how the GAN-associated mu-
tations affect the specific interaction, we tested four ad-
ditional mutant gigaxonin, 18insA, R15S, V82F, R545C,
and R293X (see diagram in Figure S2) [9], in transfected
cells. The expression of the 18insA mutant is barely de-
tectable. Although the BTB domain mutants, R15S and
V82F, display no disruptive effect on the specific inter-
action (Figure 1D, lanes 2 and 3), the mutations in the
kelch-repeat domain, R293X (nonsense mutation) and
R545C (point mutation), resulted in a complete loss of
the binding activity with TBCB in cotransfected cells
(Figure 1D, lanes 4 and 5), demonstrating that an effec-
tive interaction with TBCB requires a functional kelch-
repeat domain. Out of 24 distinct mutations identified
in human GAN patients [9–12], 12 nonsense mutations
that cause complete or partial loss of the kelch repeats
and six point mutations in the kelch-repeat domain
may consequently lead to disruption of the gigaxonin-
TBCB interaction.
Gigaxonin Controls TBCB Degradation
via the Ubiquitin-Proteasome Pathway
GAN is postulated to be a disorder of the functional loss
of gigaxonin [13]. To understand the pathological effect
caused by the disrupted gigaxonin-TBCB interaction,
we first examined TBCB expression in the gan null
mice (a manuscript on the gene-targeting strategy and
KO characterization is in process elsewhere). The sam-
ples of total mouse-brain lysates were analyzed by se-
quential immunoblotting with antibodies to gigaxonin,
b-tubulin, a-tubulin, TBCB, and actin. As judged by three
independent assays, the absence of gigaxonin led to
a substantially elevated level of TBCB protein in the
null animals (Figure 2A). A modest increase of a- and
b-tubulin was also observed in comparison to the un-
changed actin control (Figure 2A). In contrast to the ele-
vated protein level, RT-PCR results revealed a moderate
downregulation of TBCB transcription in comparison to
a-tubulin, GAPDH, and actin in the null samples (Fig-
ure 2B). The quantitative real-time PCR has further con-
firmed this observation (Figure 2C). Thus, the increased
level of TBCB was rather due to protein accumulation.
Gigaxonin is distantly related to the evolutionarily
conserved BTB/kelch superfamily [9, 13] that may be in-
volved in the ubiquitin-proteasome-dependent protein
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xonin Binds to the N Terminus of TBCB
(A) pGBKT7/gigaxonin (Gig, amino acids 11–
584) binds pGADT7/TBCBC1 (amino acids
32–244) in the yeast two-hybrid screen.
pGBKT7/P53 with pGADT7/TD1-1: positive
control. pGBKT7/P53 with pGADT7/TBCBC1
and pGBKT7/gigaxonin with pGADT7/TD1-1:
negative controls.
(B) HA-TBCB was cotransfected in COS7 cells
with either the full-length ([F], lane 1) or N-ter-
minal BTB domain ([N], lane 2) or with the
C-terminal kelch-repeat domain ([C], lane 3)
of Flag-tagged gigaxonin. Conversely, HA-
tagged Gigaxonin was cotransfected with
full-length ([F], lane 4), N-terminal ([N], lane
5), and C-terminal ([C2], lane 6) Flag-tagged
TBCB. The TBCB-gigaxonin association was
examined by co-IPs with anti-Flag M2, fol-
lowed by immunoblottings either with an
anti-HA (upper panels) or with anti-Flag (mid-
dle panels). The expression of HA-tagged
proteins was also confirmed (bottom panels).
(C) Transfected wild-type Flag-gigaxonin (up-
per panel, lane 3), but not the mutant R293X
(upper panel, lane 4), co-immunoprecipitates
endogenous TBCB from COS7 cells. Lanes 1
and 2 are the controls from untransfected
cell lysates or sham IPs, respectively. The
blot was also probed with anti-Flag to confirm
the expression of Flag proteins (lower panel).
(D) The HA-TBCB was cotransfected with
wild-type Flag-gigaxonin (WT) or the mutants
(R15S, V82F, R545C, or R293X). The TBCB
bound gigaxonin was co-IPed with anti-Flag
M2 and detected by WB with anti-HA (top
panel). The middle and bottom panels were
control blots of anti-Flag and anti-HA, respec-
tively. An asterisk indicates some non-spe-
cific reactions, and an ampersand indicates
the dimerization of the BTB domain.degradation [14–18]. The accumulation of TBCB protein
in the gigaxonin’s null mice prompted us to investigate
a potential role of gigaxonin in substrate-specific protein
degradation. HA-tagged gigaxonin and Flag-tagged
TBCB were ectopically coexpressed in COS7 cells. In-
deed, in cells transfected with a fixed amount of Flag-
TBCB and varying amounts of HA-gigaxonin, the in-
crease of HA-gigaxonin expression was accompanied
by a decrease of Flag-TBCB (Figure 2D, left panel). In
contrast, TBCA, another tubulin chaperone protein, dis-
played no such reduction (Figure 2D, right panel). These
results suggest that gigaxonin specifically controls
TBCB’s degradation. To further evaluate TBCB’s stabil-
ity, we employed the strategy of suppressing protein
translation by utilizing cycloheximide (CHX) to study
TBCB’s degradation. As determined by three indepen-
dent experiments, only half of the ectopic HA-TBCB re-
mained less than 2 hr after the addition of CHX in the
presence of Flag-gigaxonin (Figure 2E, lanes 1–5), in
contrast to TBCB’s marked stability in gigaxonin’s ab-
sence (Figure 2E, lane 6), supplying additional evidence
for its role in TBCB’s degradation. Likewise, the overex-
pression of gigaxonin also significantly reduces in vivo
TBCB levels (Figure 2F, lane 2), which could be reversed
by applications of proteasome inhibitor (PI) (Figure 2F,
lane 4). Take together, our results present gigaxonin as
an important player in controlling TBCB protein stability,and the fact that PI reverses TBCB turnover implicates
the involvement of the ubiquitin-proteasome system
(UPS).
Recombinant gigaxonin was found in immunoprecipi-
tated complex with Cul-3 [16]. If TBCB is a gigaxonin-
mediated UPS substrate, TBCB is expected to become
covalently conjugated with poly-ubiquitin when gigaxo-
nin is present. To test this hypothesis, we cotransfected
Myc-tagged ubiquitin with Flag-TBCB. In the protein
complex concentrated by immunoprecipitation with
anti-Flag-TBCB, TBCB formed a high-molecular-mass
complex consistent with the conjugation of poly-
ubiquitin tags in the presence of gigaxonin (Figure 3A,
lane 4), and the poly-ubiquitin conjugation of TBCB
was dramatically enhanced with PI addition (Figure 3A,
lane 5). Similarly, the endogenous TBCB also displayed
characteristic high molecular shifts of TBCB in the pres-
ence of HA-gigaxonin and PI (Figure 3B, lane 2). In con-
trast, without gigaxonin, TBCB exhibited no evidence
of poly-ubiquitination even when an excess of ubiquitin
and PI was supplied (Figure 3B, lanes 1). Moreover, the
GAN-associated mutations, V82F, R293X, and R545C,
disrupted gigaxonin’s function in promoting TBCB’s
ubiquitination (Figure 3A, lanes 8–10). The R15S mutant,
however, functioned similarly to wild-type gigaxonin
(Figure 3A, lane 7). Interestingly, although the V82F
mutant retained binding activity to TBCB, it failed to
Current Biology
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dation of TBCB
(A) Brain lysates (25 mg) from wild-type (WT,
lane 1) or gigaxonin-knockout (KO, lane 2)
mice were analyzed with antibodies to, se-
quentially, gigaxonin, b-tubulin, a-tubulin,
TBCB, and actin.
(B) RT-PCRs were conducted on mRNAs of
WT or KO with multiple primer pairs to
TBCB (215 bp), actin (550 bp), a-tubulin (800
bp), and GAPDH (1 Kb).
(C) Real-time PCR from three independent tri-
als confirmed that the TBCB mRNA level re-
mains unchanged in the KO samples. Error
bars represent means 6 S.D.; p > 0.05 with
Student’s t test.
(D) Increased gigaxonin expression corre-
lates with a decreased level of TBCB. A fixed
amount of Flag-TBCB or TBCA (0.75 mg) and
an increasing amount of HA-gigaxonin were
used (0.25, 0.5, 1, or 1.5 mg for lanes 2–5;
0.5, 1, or 1.5 mg for lanes 6–8). Lane 1: TBCB
only.
(E) Stability assays of HA-TBCB. The co-
transfections were treated with cyclohexa-
mide (CHX) at 6 3 1023 mg/ml for 0–8 hr
(lanes 1–5). Note the stability of TBCB protein
in gigaxonin’s absence (lane 6).
(F) Gigaxonin overexpression reduces en-
dogenous TBCB levels (compare lanes 2
and 3 with lane 1). PI addition reversed the
effect (compare lane 4 with lanes 2 and 3).promote TBCB poly-ubiquitination (Figure 3A, lane 8),
suggesting that gigaxonin may have additional activities
required in controlling TBCB’s ubiquitination. These re-
sults uncovered the fact that in contrast to its mutant
counterpart, gigaxonin is required in linking poly-ubiqui-
tin tags to TBCB. To obtain additional in vivo evidence,
we compared the ubiquitination of TBCB in the presence
or the absence of gigaxonin in cultured wild-type or
knockout (KO) neurons. When Flag-TBCB was trans-
fected for 3 days, overexpressed Flag-TBCB in wild-
type neurons apparently activated the endogenous
UPS and became costained with ubiquitins (Figures
S3A–S3D). In the gigaxonin null neurons, the substan-
tially accumulated Flag-TBCB was negative for ubiquitinstaining (Figures S3E–S3H), further supporting the no-
tion that TBCB’s ubiquitination requires functional giga-
xonin. It is possible that mutations in gigaxonin could
cause substrate overstabilization, leading to deleterious
consequences.
Overexpressing TBCB Could Recapitulate
the Microtubule Pathology in GAN
GAN is featured pathologically by generalized cytoskel-
etal abnormalities, including few microtubules [2]. Aber-
rations in the cytoskeletal network are often observed
prior to other signs of severe neurodegeneration. The mi-
crotubule pathology in human GAN was also confirmed
in the pre-phenotypic gan null animals. Regardless ofFigure 3. Gigaxonin Is Required for TBCB’s Ubiquitination
(A) The cotransfected cells were subjected to co-IPs with anti-Flag (Flag-TBCB) and immunoblotted with anti-Myc (Myc-Ubiquitin) to detect
Flag-TBCB ubiquitination. Note: wild-type gigaxonin and R15S promoted TBCB’s ubiquitinations (lanes 4–7), but other mutants did not (lanes
8–10). (B) Poly-ubiquitin conjugations of endogenous TBCB in the presence of PI (MG132) and gigaxonin (lane 2). Note: without functional giga-
xonin, TBCB shows no poly-ubiquitinations (lanes 1 and 3). An asterisk indicates some non-specific background reactions.
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lates Microtubule Pathology in Cells
(A–F) COS7 cells were transfected with Flag-
TBCB (A–C) or cotransfected with Flag-TBCB
and HA-gigaxonin (HA-Gig) (D–F) and were
then costained with antibodies to tubulin
and Flag. (G–O) wild-type cortical neurons
transfected with either GFP (G–I) or Flag-
TBCB (J–L) or cotransfected with HA-Gig
and Flag-TBCB (M–O) were processed for
double immunofluorescence microscopy
with GFP and mouse anti-tubulin (G–I) or rab-
bit anti-Flag and mouse anti-tubulin (J–O).
Arrowheads point to the transfected cells.
The scale bar represents 30 mm in all panels.neurofilament density or myelination, the common and
consistent feature found in all areas is a significant
reduction of microtubules (Figures S4C and S4F). The
observations at the EM level were further sustained by
immunostaining on cultured neurons, revealing that mi-
crotubule staining in the null neurons was notably weak-
ened (Figures S5D–S5F), in comparison with that in the
wild-type controls (Figures S5A–S5C). Quantitative anal-
ysis in the null animals confirmed the microtubule pathol-
ogy, revealing an average decrease of approximately
51% of microtubule density both in and outside of the
nervous system at postnatal weeks 20–26.
TBCB is one of the five tubulin folding cofactors
(TBCA, TBCB, TBCC, TBCD, and TBCE) that coordi-
nately control functional heterodimerizations of a/b-
tubulin to form the microtubule network [5, 8, 19]. Re-
cently, a direct involvement of tubulin chaperones in
human diseases of protein folding has become increas-
ingly evident [20–23]. It has been demonstrated that
overexpression of various tubulin folding cofactors de-
stabilizes microtubules [19, 24, 25]. To understand the
pathogenic contributions by TBCB protein accumula-tion to the substantial reduction of microtubules in gan
null mice, we first manipulated COS7 cells by overex-
pressing TBCB and thus forcing its cellular accumula-
tion. We found a dramatic decrease in the intensity of
microtubule staining in the transfected cells by using
antibodies to a-tubulin (Figures 4A–4C) or b tubulin
(not shown) after 48 hr transfection, and the disappear-
ance of microtubules correlates with TBCB’s accumu-
lated level. The microtubule-network disruption could
be restored when wild-type gigaxonin was coexpressed
with TBCB in the cells (Figures 4D–4F). Consistent with
the finding in vitro, only the coexpression of R15S mu-
tant with TBCB displayed restoration of the microtubule
network (Figures S6A–S6C), whereas V82F, R293X, and
R545C mutants exhibited no rescuing effects (Figures
S6D–S6L). The observed functional retaining of the
R15S mutant implies that controlling TBCB’s degrada-
tion is not gigaxonin’s only function and that this muta-
tion works by a different mechanism than the others. We
next sought to further assess the correlation between
accumulated TBCB and abnormal microtubules in cul-
tured primary neurons. After the initial 4–5 days, the
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The neurons were then transiently transfected with
TBCB or GFP for various numbers of days. Notably, it
takes longer for Flag-TBCB protein to be accumulated
in neurons than in COS7 cells. However, usually 3–4
days after transfection, the microtubules in more than
two-thirds of the TBCB-overexpressing neurons be-
came barely detectable (Figures 4J–4L), similar to the re-
sults in TBCB-overexpressing COS7 cells. Again, the mi-
crotubule staining could be restored by gigaxonin
coexpression (Figures 4M–4O), further implicating the
importance of gigaxonin in the maintenance of the mi-
crotubule network. As a control, GFP-overexpressing
neurons retained their strong microtubule staining over
the entire time course up to two weeks (Figures 4G–
4I). By day 6–7 post-transfection, approximately 60%
of the TBCB-overexpressing neurons began to lose their
normal morphology, suggesting that disruption of the
microtubule network precedes neurodegeneration or
cell death. Our data add important evidence that accu-
mulated TBCB is a microtubule-destabilizing factor
and strongly suggest that accumulation of TBCB in cells
may be a causative factor responsible for microtubule
pathology in human GAN.
Conclusions
We have characterized the specific interaction of gigaxo-
nin with TBCB and demonstrated that gigaxonin controls
protein degradation of TBCB via the ubiquitin-protea-
some pathway; this function is critical to the mainte-
nance of the microtubule network. Gigaxonin is a distinct
cytoskeleton regulatory protein that may represent a
general pathological target for other neurodegenerative
disorders with cytoskeleton alterations, as well as de-
fects in UPS. Many questions, including how accumu-
lated TBCB causes low microtubule density, remain to
be addressed. In addition, future studies should eluci-
date whether the densely accumulated NFs in GAN are
a compensatory response to the abnormal microtubule
network or whether gigaxonin controls the stability of a
yet-unknown partner that primarily involves in IF network.
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Supplemental Data including six additional figures are available with
this article online at http://www.current-biology.com/cgi/content/
full/15/22/2050/DC1/.
Acknowledgments
We thank Dr. Susanna M. Grzeschik for technical advice on real-time
PCR; we also thank other colleagues of the Yang Lab for scientific
discussions. This work was supported by research grants from the
Muscular Dystrophy Association and from the National Institutes
of Health (NS42791 and NS43281) to Y.Y.
Received: June 13, 2005
Revised: October 5, 2005
Accepted: October 7, 2005
Published: November 21, 2005
References
1. Berg, B.O., Rosenberg, S.H., and Asbury, A.K. (1972). Giant
axonal neuropathy. Pediatrics 49, 894–899.
2. Taratuto, A.L., Sevlever, G., Saccoliti, M., Caceres, L., and
Schultz, M. (1990). Giant axonal neuropathy (GAN): An immuno-histochemical and ultrastructural study report of a Latin Ameri-
can case. Acta Neuropathol. (Berl.) 80, 680–683.
3. Ciechanover, A., and Brundin, P. (2003). The ubiquitin protea-
some system in neurodegenerative diseases: Sometimes the
chicken, sometimes the egg. Neuron 40, 427–446.
4. Sherr, C.J. (2004). Principles of tumor suppression. Cell 116,
235–246.
5. Tian, G., Lewis, S.A., Feierbach, B., Stearns, T., Rommelaere, H.,
Ampe, C., and Cowan, N.J. (1997). Tubulin subunits exist in an
activated conformational state generated and maintained by
protein cofactors. J. Cell Biol. 138, 821–832.
6. Ding, J., Liu, J.J., Kowal, A.S., Nardine, T., Bhattacharya, P.,
Lee, A., and Yang, Y. (2002). Microtubule-associated protein
1B: A neuronal binding partner for gigaxonin. J. Cell Biol. 158,
427–433.
7. Watanabe, T.K., Shimizu, F., Nagata, M., Kawai, A., Fujiwara, T.,
Nakamura, Y., Takahashi, E., and Hirai, Y. (1996). Cloning, ex-
pression, and mapping of CKAPI, which encodes a putative
cytoskeleton-associated protein containing a CAP-GLY domain.
Cytogenet. Cell Genet. 72, 208–211.
8. Cowan, N.J., and Lewis, S.A. (1999). A chaperone with a hydro-
philic surface. Nat. Struct. Biol. 6, 990–991.
9. Bomont, P., Cavalier, L., Blondeau, F., Ben Hamida, C., Belal, S.,
Tazir, M., Demir, E., Topaloglu, H., Korinthenberg, R., Tuysuz, B.,
et al. (2000). The gene encoding gigaxonin, a new member of the
cytoskeletal BTB/kelch repeat family, is mutated in giant axonal
neuropathy. Nat. Genet. 26, 370–374.
10. Kuhlenbaumer, G., Young, P., Oberwittler, C., Hunermund, G.,
Schirmacher, A., Domschke, K., Ringelstein, B., and Stog-
bauer, F. (2002). Giant axonal neuropathy (GAN): Case report
and two novel mutations in the gigaxonin gene. Neurology 58,
1273–1276.
11. Bomont, P., Ioos, C.,Yalcinkaya,C.,Korinthenberg,R.,Vallat, J.M.,
Assami,S., Munnich,A.,Chabrol, B., Kurlemann,G., Tazir, M., etal.
(2003). Identification of seven novel mutations in the GAN gene.
Hum. Mutat. 21, 446–447.
12. Bruno, C., Bertini, E., Federico, A., Tonoli, E., Lispi, M.L.,
Cassandrini, D., Pedemonte, M., Santorelli, F.M., Filocamo, M.,
Dotti, M.T., et al. (2004). Clinical and molecular findings in pa-
tients with giant axonal neuropathy (GAN). Neurology 62, 13–16.
13. Timmerman, V., De Jonghe, P., and Van Broeckhoven, C. (2000).
Of giant axons and curly hair. Nat. Genet. 26, 254–255.
14. Pintard, L., Willis, J.H., Willems, A., Johnson, J.L., Srayko, M.,
Kurz, T., Glaser, S., Mains, P.E., Tyers, M., Bowerman, B.,
et al. (2003). The BTB protein MEL-26 is a substrate-specific
adaptor of the CUL-3 ubiquitin-ligase. Nature 425, 311–316.
15. Xu, L., Wei, Y., Reboul, J., Vaglio, P., Shin, T.H., Vidal, M.,
Elledge, S.J., and Harper, J.W. (2003). BTB proteins are sub-
strate-specific adaptors in an SCF-like modular ubiquitin ligase
containing CUL-3. Nature 425, 316–321.
16. Furukawa, M., He, Y.J., Borchers, C., and Xiong, Y. (2003). Tar-
geting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin
ligases. Nat. Cell Biol. 5, 1001–1007.
17. Geyer, R., Wee, S., Anderson, S., Yates, J., and Wolf, D.A. (2003).
BTB/POZ domain proteins are putative substrate adaptors for
cullin 3 ubiquitin ligases. Mol. Cell 12, 783–790.
18. Wilkins, A., Ping, Q., and Carpenter, C.L. (2004). RhoBTB2 is
a substrate of the mammalian Cul3 ubiquitin ligase complex.
Genes Dev. 18, 856–861.
19. Radcliffe, P.A., Hirata, D., Vardy, L., and Toda, T. (1999). Func-
tional dissection and hierarchy of tubulin-folding cofactor
homologues in fission yeast. Mol. Biol. Cell 10, 2987–3001.
20. Schwahn, U., Lenzner, S., Dong, J., Feil, S., Hinzmann, B., van
Duijnhoven, G., Kirschner, R., Hemberger, M., Bergen, A.A.,
Rosenberg, T., et al. (1998). Positional cloning of the gene for
X-linked retinitis pigmentosa 2. Nat. Genet. 19, 327–332.
21. Martin, N., Jaubert, J., Gounon, P., Salido, E., Haase, G.,
Szatanik, M., and Guenet, J.L. (2002). A missense mutation in
Tbce causes progressive motor neuronopathy in mice. Nat.
Genet. 32, 443–447.
22. Parvari, R., Hershkovitz, E., Grossman, N., Gorodischer, R.,
Loeys, B., Zecic, A., Mortier, G., Gregory, S., Sharony, R.,
Kambouris, M., et al. (2002). Mutation of TBCE causes
Gigaxonin Recruits TBCB for Degradation
2055hypoparathyroidism-retardation-dysmorphism and autosomal
recessive Kenny-Caffey syndrome. Nat. Genet. 32, 448–452.
23. Bommel, H., Xie, G., Rossoll, W., Wiese, S., Jablonka, S.,
Boehm, T., and Sendtner, M. (2002). Missense mutation in the
tubulin-specific chaperone E (Tbce) gene in the mouse mutant
progressive motor neuronopathy, a model of human motoneu-
ron disease. J. Cell Biol. 159, 563–569.
24. Bhamidipati, A., Lewis, S.A., and Cowan, N.J. (2000). ADP ribo-
sylation factor-like protein 2 (Arl2) regulates the interaction of
tubulin-folding cofactor D with native tubulin. J. Cell Biol. 149,
1087–1096.
25. Martin, L., Fanarraga, M.L., Aloria, K., and Zabala, J.C. (2000).
Tubulin folding cofactor D is a microtubule destabilizing protein.
FEBS Lett. 470, 93–95.
